Threat to value of CE-marking: Eucomed wants EU strategy counterfeiting
This article was originally published in Clinica
A strategy to prevent counterfeiting and piracy in medical device trade is essential, European medical technology association, Eucomed, says. The association is concerned that if this issue is not tackled, there will be a real threat to the value of the CE mark and that EU R&D will be discouraged. A legal framework is necessary that allows quick and effective action to eliminate counterfeited products from the market place and the industry must support the latest initiatives that are currently being actively pursued by the European Commission in this respect, the association asserts.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.